Skip to main content

Site notifications

TGA provisionally approves Merck Sharp & Dohme (Australia) Pty Ltd's oral COVID-19 treatment, LAGEVRIO (molnupiravir)

On 18 January 2022 the TGA granted provisional approval to Merck Sharp & Dohme (Australia) Pty Ltd for its oral COVID-19 treatment, LAGEVRIO (molnupiravir).

Last updated

Help us improve the Therapeutic Goods Administration site